Director John B. Schmieder not standing for re-election at 2023 annual meeting

MESA LABORATORIES INC /CO/

John B. Schmieder, director since 2015, will not stand for re-election at 2023 annual meeting.
Currently Chair of Nominating and Governance Committee and member of Audit Committee.
Decision not related to any disagreement with Mesa's operations, policies, or practices.
He will continue to serve as director through the date of the annual meeting.
Committee assignments to be determined prior to his departure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John B. Schmieder

Director

MLAB · MESA LABORATORIES INC /CO/

Filed: May 8, 2023, 7:59 PM ET

On May 3, 2023, John B. Schmieder, member of the Board of Directors (the “Board”), current Chair of the Nominating and Governance Committee, and member of the Audit Committee, informed the Board of Mesa Laboratories, Inc. that he has decided not to stand for re-election at the 2023 annual meeting of shareholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John B. Schmieder departed as Director at MESA LABORATORIES INC /CO/.

Action: decided not to stand for re-election
Role: Director

Exact text from the filing

On May 3, 2023, John B. Schmieder, member of the Board of Directors (the “Board”), current Chair of the Nominating and Governance Committee, and member of the Audit Committee, informed the Board of Mesa Laboratories, Inc. that he has decided not to stand for re-election at the 2023 annual meeting of shareholders.

View on SEC.gov

MESA LABORATORIES INC /CO/ filing history →

Source: SEC EDGAR

accession 0001437749-23-012905

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.